On 21 May, the international Journal of Alzheimer’s Disease issued a mini-forum revolving around three publications by the Innovative Medicines Initiative’s PharmaCog project.
The PharmaCog project started in 2010 and had a duration of 5 years. Although finished, it keeps on producing results. These findings focus on the study of the usefulness of different biomarkers to help understand how Alzheimer’s disease will progress in people at the early stages, namely those who have mild cognitive impairments and memory problems but still manage their activities of daily living.
Alzheimer Europe has been an active partner in this project and references to the results can be found on the Neuronet Knowledge Base:
https://kb.imi-neuronet.org/admin/publications/project/25
The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
